Analytical Data
-
Gene name
IGFBP1
- Application
-
Alternative Names
Igfbp1; Igfbp-1; Insulin-like growth factor-binding protein 1; IBP-1; IGF-binding protein 1; IGFBP-1
-
Species
Rat
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P21743
-
Expression Region
26-272aa
-
Molecular Weight
42.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Insulin-like growth factor binding protein 1 (IGFBP1) is a key regulator of insulin-like growth factors (IGFs), which play crucial roles in cell growth, differentiation, and metabolism. IGFBP1 modulates the availability and activity of IGFs by binding to them, thereby influencing various physiological processes, including fetal development, metabolism, and tissue repair. Research has indicated that altered levels of IGFBP1 are associated with several pathophysiological conditions, such as obesity, diabetes, and certain cancers, making it a potential biomarker and therapeutic target. The recombinant production of IGFBP1 has garnered significant interest as it allows for detailed studies on its structure-function relationships and therapeutic applications. Advances in recombinant DNA technology have enabled the efficient expression and purification of IGFBP1, facilitating investigations into its molecular interactions and biological effects. Moreover, recombinant IGFBP1 has been utilized in various in vitro and in vivo studies to explore its role in regulating IGF signaling pathways. Understanding the functional mechanisms of IGFBP1 is crucial for developing novel strategies for disease intervention and management, highlighting its significance in both basic research and clinical applications. As such, the exploration of IGFBP1 as a recombinant protein holds promise for elucidating its biological functions and therapeutic potential in metabolic and neoplastic diseases.
